The stakes are considerable. Molluscan shellfish aquaculture is now the third largest group of farmed aquatic animals after finfish and crustaceans, and cupped oysters alone produced 6.2 million tons in 2022, making them the second largest farmed aquatic species group by weight globally. Selective breeding for commercially desirable traits such as growth, meat quality, and disease resistance has become a central component of industry growth, and genomic selection sits at the forefront of these efforts. The approach relies on inexpensive, high-throughput genotyping of large numbers of broodstock candidates to calculate a genomic estimated breeding value for each animal. Until now, that calculation has been bottlenecked by the laborious and potentially injurious step of extracting tissue from live oysters, which requires anesthesia to induce incomplete paralysis of the adductor muscle, followed by careful removal of gill or mantle tissue with scissors and forceps. Gaping varies among individuals, tissue excision can cause stress or mortality, and breeding programs often operate at a scale that requires sampling by less experienced personnel such as interns, raising the risk of injury to valuable animals.

The research team designed a series of experiments to test whether gentler alternatives could match the genotyping quality of the adductor muscle reference. In the Eastern oyster experiments, oysters from the Choptank River in Maryland were relaxed in 5 percent magnesium sulfate in aerated seawater for four to eight hours until they gaped. Researchers then sampled DNA in three ways: a cytology brush swab rotated briefly against the adductor muscle and mantle, a mantle tissue clip excised from the edge of the shell, and environmental DNA collected by filtering water in which individual oysters had been housed for eight hours. After the non-lethal sampling, oysters were shucked and adductor tissue was taken as the reference genotype. In a second experiment, the cytology brush was compared to two cheaper alternatives: a cotton-tipped swab costing roughly four cents and a disposable nylon eyelash brush costing about two cents per swab. Eastern oyster samples were genotyped on a 66K single nucleotide polymorphism (SNP) array, while Pacific oyster samples were evaluated using PCR-based genotyping-by-sequencing with amplicon panels of 592 and 288 loci.

The DNA yields told an interesting story. Cytology brush swabs produced the highest DNA concentrations in the first Eastern oyster experiment, averaging 423.2 nanograms per microliter, far exceeding adductor muscle at 77.3, mantle tissue at 50.8, and eDNA at 18.9 nanograms per microliter. In the second experiment, where swabs were stored in ethanol for several weeks before extraction, the two brush swabs still outperformed the cotton swab, with mascara brushes averaging 151.3 and cytology brushes 121.7 nanograms per microliter, compared to 28.3 for cotton tips. DNA quality, assessed by molecular weight on agarose gels, was variable among swab types, with adductor samples showing the most consistently high molecular weight extracts. Yet this apparent difference in quality had little impact on the ultimate genotyping outcome, a finding the authors attribute to the relatively short probes used on the SNP array, which are only about 20 to 60 base pairs long and can still hybridize effectively to fragmented DNA.

Genotype concordance, the key measure of whether a non-lethal sample produces the same genetic calls as the lethal reference, was remarkably high across the board. An average of 57,300 SNPs were assessed for concordance in the Eastern oyster experiments, and the mean non-concordance rate across all sample types was just 0.56 percent. The mascara swab recorded the lowest rate at 0.30 percent, the cytology brush came in at 0.58 percent, and mantle clips produced 0.82 percent. There was no statistically significant difference in non-concordance among tissue and swab types, and no relationship between DNA molecular weight category and concordance rate. Cotton swabs produced less consistent results, with four of ten samples failing quality control, while eDNA samples performed poorly overall, with more than half failing QC and only four of ten producing a usable call rate. The authors suggest that the eight-hour incubation was insufficient to accumulate enough oyster DNA for array genotyping, noting that a previous study of European flat oysters achieved high concordance with eDNA only after 72 hours of incubation, a residence time that presents substantial logistical challenges for breeding programs requiring rapid sampling.

The Pacific oyster experiments extended the findings to sequencing-based genotyping. In the first experiment, 48 animals were swabbed with PurFlock Ultra swabs and genotyped on a 592-locus amplicon panel. Twelve samples failed quality control, and after removing these poor performers, no significant difference in genotype call rate existed between swab and adductor samples. SNP genotype concordance was high, with only samples that failed QC showing greater than 1 percent non-concordance. All mismatching cases involved a homozygote and heterozygote pair, with no cases of reference homozygote to alternate homozygote, and no strong bias toward either genotype class within a single sample type, suggesting that PCR amplification did not preferentially amplify one allele but had a random chance of amplifying either allele within heterozygotes.

A microhaplotype analysis, which examines multiple linked SNPs together as a single haplotype allele, produced slightly higher non-concordance rates averaging 3.3 percent in the first experiment and roughly 4 percent in the second. However, the vast majority of these mismatches involved a homozygote-to-heterozygote discrepancy in which the missing allele was actually present in the raw sequencing data. In the second experiment, 537 of 547 homozygote-to-heterozygote mismatches had the missing allele identified in the sequence data, most often as the second-ranked allele. The authors conclude that rudimentary genotype calling parameters, rather than true biological or sampling errors, are likely driving the higher error rate, an unsurprising outcome given the nascent implementation of microhaplotypes in aquaculture research and the ongoing development of the panels. As calling methods improve, non-concordance rates are expected to drop to those observed in SNP genotyping or lower.

Survival and tag retention were also evaluated in the field. In the second Pacific oyster experiment, 100 oysters each were assigned to cytology brush, microbrush, mantle clipping, and control treatments, tagged with paired glue-on tags, and deployed subtidally in Yaquina Bay, Oregon, from early July to early August 2025. After 27 days, mean survival across all replicates was 93.25 percent, with no statistical difference between any DNA sampling method and the control. Control treatments survived at 100 percent and 84 percent in the two basket stacks, microbrush at 96 percent in both, cytology brush at 94 and 86 percent, and mantle clipping at 100 and 90 percent. No oysters lost both tags, and only three lost a single tag during the deployment. While 27 days is a relatively short observation period, the authors note that potential broodstock candidates in a genomic selection program are likely to be brought onshore for artificially induced maturation within a few months of sampling, making the high survival and tag retention over the first month promising for scalable, high-throughput application.

The practical implications are significant. Brush swabs are faster and easier to implement than tissue excision, and less experienced staff are less likely to seriously injure animals when using a softer swab compared to clipping tissue with sharp implements. The mascara swab is roughly tenfold cheaper than the cytology swab, and the choice among brush types will likely be predicated on cost, availability, and user preference. The finding that genotyping-by-sequencing appears robust to variability in sample quality is particularly important, because it means that when swabbing occurs for large numbers of animals in a short time period, samples with poorer genotyping call rates can be treated as reliable rather than more error prone. The authors suggest that non-lethal swab DNA collection provides genotype data equivalent to mantle or adductor tissue-derived data while likely causing less acute stress to the animal, and that the method is amenable to large-scale DNA capture efforts often undertaken by volunteers or less experienced personnel in breeding program operations.

As genomic selection becomes increasingly applied in shellfish breeding programs to advance commercially desirable phenotypes, efficient and rapid methods for non-lethal biopsy are essential for generating the high-quality genotype data needed for accurate breeding value estimation. This study demonstrates that multiple swab types can generate high-quality DNA for sequencing and genotyping on multiple commonly used platforms, from SNP arrays to amplicon sequencing panels. The high post-sampling survival, genotype concordance, and tag retention suggest that swabbing can serve as an effective, high-throughput, and relatively benign method for obtaining the DNA necessary to generate genomic estimated breeding values. For oyster restoration and production aquaculture alike, the simple act of brushing DNA from between the shells may prove to be an important step in bringing advanced genetic tools to the animals that feed a growing global demand for bivalve seafood.

,

Subject of Research: DNA sampling between the shells: evaluating non-lethal DNA sampling methods in oysters for high-throughput genotyping

Article Title: DNA sampling between the shells: evaluating non-lethal DNA sampling methods in oysters for high-throughput genotyping

Article References: Plough, L. V., Young, M. E., Schwartz, L., Pandelides, A. F., Stauffer, B., & Thompson, N. F. (2026). DNA sampling between the shells: evaluating non-lethal DNA sampling methods in oysters for high-throughput genotyping. Frontiers in Aquaculture, 5, Article 1848821. https://doi.org/10.3389/faquc.2026.1848821

Image Credits: AI Generated

DOI: 10.3389/faquc.2026.1848821

Keywords: oysters, genotyping, genomic selection, non-lethal sampling, DNA swabbing, SNP array, genotyping-by-sequencing, microhaplotype, aquaculture, broodstock, Crassostrea virginica, Crassostrea gigas

The challenge that Amira addresses begins with how resistance genes are organised in bacterial genomes. Genes conferring resistance to antibiotics are frequently multicopy, meaning that a single bacterial genome may carry two, three or many more copies of the same gene, and these copies are often enriched at repeat loci, regions where long stretches of near-identical sequence recur. These repetitive neighbourhoods are precisely where genome assemblers tend to fail, collapsing distinct copies into a single contig or producing fragmented, unreliable reconstructions. Because the exact sequence and copy number of a resistance gene can determine how resistant a pathogen actually is, errors at these loci translate directly into errors in predicting a bacterium’s drug susceptibility.

Existing computational strategies split into two broad camps, and both struggle with the multicopy problem. The first relies on obtaining a correct genome assembly before searching it for resistance genes, which as noted is unreliable when the genes of interest live in repeats. The second avoids assembly altogether and instead works with k-mers, short sequences of a fixed length extracted directly from the reads. K-mer methods can flag the presence of a resistance gene, but they have a fundamental blind spot: when a gene exists in several slightly different copies, k-mers shared between those copies cannot be attributed to any particular one, so the tools cannot reliably distinguish the different copies from one another or determine how many copies are present.

Amira takes a different path, building what the authors call gene-space de Bruijn graphs. A de Bruijn graph is a classic data structure in bioinformatics in which sequences are broken into short overlapping words and connected according to how those words overlap, producing a network that encodes sequence similarity and variation. Rather than building such a graph over an entire genome, Amira restricts its graphs to the space of known antimicrobial resistance genes, effectively zooming in on the regions that matter for surveillance. Reads from long-read sequencing technologies, which produce fragments long enough to span repetitive regions, are then threaded through these gene-space graphs, allowing the algorithm to assign each read to a specific copy of a resistance gene.

This read-assignment step is the heart of the method. Once reads have been associated with distinct gene copies, the per-copy depth of coverage becomes visible, which enables accurate copy-number estimation, and the reads assigned to each copy can be assembled to recover the precise nucleotide sequence of that copy. In effect, Amira converts a global assembly problem, which is hardest exactly where resistance genes live, into a set of much smaller, localised assembly problems that are tractable because the graph structure has already disentangled the copies. The approach preserves the ability of long reads to resolve repeats while sidestepping the weaknesses of whole-genome assembly and the copy-blindness of k-mer counting.

The performance of the method was evaluated across a range of settings. In simulations, in curated samples where the true composition of the genome was known, and in public datasets, the authors report that Amira improved both copy-number recall and nucleotide accuracy compared with existing methods. Copy-number recall refers to the tool’s ability to correctly identify how many copies of a gene are present, while nucleotide accuracy measures how faithfully the reconstructed sequence matches the true gene sequence, a critical property because small sequence differences within a resistance gene family can correspond to meaningful differences in resistance phenotype.

The evaluation drew on a substantial collection of bacterial isolates. Supplementary materials accompanying the paper describe work with reference assemblies spanning dozens of bacterial species, an Escherichia coli pan-genome reference used both to construct the method’s gene space and to evaluate it, and a truth evaluation involving 32 Escherichia coli isolates with paired Nanopore and Illumina sequencing data. The team also worked with Klebsiella pneumoniae isolates, another major pathogen in which resistance genes are often found in complex repeat structures, and examined plasmid structural variants, reflecting the fact that resistance genes frequently travel on mobile plasmids that shuffle between bacterial strains.

The practical implications reach into public health surveillance. Programmes such as PulseNet, whose Asia-Pacific team at the Centre for Pathogen Genomics contributed data to the study, depend on rapid, accurate genomic characterisation of pathogens circulating in food supplies and hospitals. A tool that can reliably genotype resistance genes directly from long reads, without waiting for or trusting a full assembly, could shorten the path from sequencer to surveillance report and reduce the risk of silent errors in multicopy genes. Because long-read sequencers are increasingly portable and can be deployed in field settings, methods that extract maximum information directly from raw reads are particularly valuable in outbreak and low-resource contexts.

The software’s computational footprint was benchmarked against competing tools across the Escherichia coli evaluation samples, information provided in the paper’s supplementary tables, giving practitioners a sense of the resources required to run the method at scale. The work was led by Daniel Anderson, supported by the European Molecular Biology Laboratory international PhD programme, with senior authorship from Zamin Iqbal, a long-standing figure in pathogen genomics and genetic epidemiology, and contributions from Trieu Le, Leandro Lima, Louise Judd and Ryan Wick, whose groups at Melbourne have deep expertise in bacterial genomics and long-read sequencing.

For a field in which the difference between one copy and three copies of a resistance gene can alter a clinical prediction, the arrival of a method designed explicitly around the structure of resistance loci marks a meaningful step. By combining gene-space de Bruijn graphs with direct read assignment from long reads, Amira offers surveillance teams and researchers a way to see resistance genes as they actually are: duplicated, repetitive and embedded in the hardest parts of the genome. The article is open access, published on 17 October 2026, and its method and benchmarks are available to the community as genome surveillance worldwide confronts the growing burden of antimicrobial resistance.

Subject of Research: Computational detection of single- and multi-copy antimicrobial resistance genes directly from long-read sequencing data

Article Title: Amira: detection of single and multi-copy antimicrobial resistance genes directly from long reads using gene-space de Bruijn graphs

Article References: Anderson, D., Lima, L., Le, T., Judd, L., Wick, R., & Iqbal, Z. (2026). Amira: detection of single and multi-copy antimicrobial resistance genes directly from long reads using gene-space de Bruijn graphs. Genome Biology. https://doi.org/10.1186/s13059-026-04301-w

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04301-w

Keywords: antimicrobial resistance, long-read sequencing, de Bruijn graphs, genome assembly, bacteria, genomics, pathogen surveillance, copy-number detection, bioinformatics, Escherichia coli, Klebsiella pneumoniae, genotyping

Factor V Leiden is the most prevalent inherited thrombophilia in many populations. It arises from a single nucleotide change, known as G1691A, in the gene encoding coagulation Factor V. That one-letter substitution makes the protein resistant to cleavage by activated protein C, the body’s natural brake on clot formation. As a result, carriers produce clots that persist longer than they should. Women who inherit one mutated copy, the heterozygous state, face a modestly elevated lifetime risk of venous thromboembolism, and that risk climbs further during pregnancy, when the coagulation system shifts naturally toward a pro-thrombotic state to protect against hemorrhage at delivery.

Beyond clotting risk, clinicians have long suspected that the mutation may also sabotage the placenta itself. Microscopic clots in placental vessels can restrict blood flow to the fetus, and this mechanism has been proposed to explain associations between thrombophilia and adverse outcomes such as recurrent pregnancy loss, preeclampsia, placental abruption, fetal growth restriction, and stillbirth. What has remained stubbornly unclear is whether giving blood thinners to women with the mutation, but without a personal history of venous thromboembolism, actually changes those outcomes. International guidelines have hesitated, and the American Society of Hematology’s 2023 guidance on thrombophilia testing reflects a broader skepticism about reflexively testing and treating asymptomatic carriers.

The new case-control study, led by Mai M. Shaker and colleagues at the Human Genetics and Genome Research Institute of the National Research Centre in Giza, set out to test that question directly. The team enrolled 200 pregnant women whose heterozygous Factor V Leiden status had been confirmed by real-time PCR and verified with Sanger sequencing, the gold-standard method for reading out the exact nucleotide sequence at the mutation site. Half of the participants had received antenatal anticoagulation, consisting of low-molecular-weight heparin with or without low-dose aspirin, while the other half had not. The two groups were comparable in baseline characteristics, including age, body mass index, and consanguinity, with no statistically significant differences, which strengthens the argument that the outcome gap reflects the treatment rather than underlying differences between the women.

The headline result is striking. Women who received anticoagulation were 2.71 times more likely to have a normal pregnancy outcome than untreated women, with a 95 percent confidence interval of 1.94 to 3.78. In epidemiological terms, a relative risk of that magnitude, with a confidence interval that excludes one by a comfortable margin, suggests a robust association rather than a statistical fluke. When the researchers dissected the individual adverse outcomes, however, the picture became more nuanced. Only small-for-gestational-age births were significantly reduced in the treated group, with a p-value of 0.02. Other complications, including miscarriage, preeclampsia, and abruption, did not differ significantly between the groups, likely because the number of events in each category was too small to detect a difference even if one existed.

The selective effect on fetal growth restriction fits the biological hypothesis particularly well. If the main harm from Factor V Leiden in pregnancy comes from microvascular clotting within the placenta, then the outcome most directly tied to chronic placental insufficiency, namely poor fetal growth, should be the one most responsive to anticoagulation. Low-molecular-weight heparin does not cross the placenta, making it the anticoagulant of choice in pregnancy, and low-dose aspirin is frequently added when placental dysfunction is suspected. Direct oral anticoagulants, by contrast, are generally avoided in pregnancy, and recent registry data continue to define their bleeding risks in non-pregnant patients with thrombophilia.

Despite the enthusiasm the headline numbers may generate, the authors themselves are careful about what the study can and cannot prove. As a case-control design, the work is observational. Women were not randomly assigned to treatment, and the decision to prescribe anticoagulation may have been influenced by clinical factors, prior pregnancy history, or physician and patient preferences that the baseline comparison of age, body mass index, and consanguinity could not fully capture. Confounding by indication can cut both ways in such studies: treated women might have been selected precisely because they were considered higher risk, which would make the observed benefit even more remarkable, or subtle differences in care and surveillance could have contributed to the outcome gap. The authors explicitly state that confirmation through large prospective randomized trials is required before the findings can translate into routine practice.

That caveat matters because the stakes are real on both sides. Anticoagulation during pregnancy means daily injections of low-molecular-weight heparin for months, along with costs, injection-site reactions, and a small but nonzero bleeding risk, particularly around delivery. Overtreating hundreds of women to benefit a subset would carry its own burden, which is why the field has been reluctant to embrace universal prophylaxis for thrombophilia carriers without prior clotting events. Conversely, for women with a history of adverse pregnancy outcomes and a confirmed heterozygous Factor V Leiden genotype, the possibility that a well-tolerated, placenta-sparing therapy could more than double the chance of a normal pregnancy is exactly the kind of signal that justifies a definitive randomized trial. Prior case-control work, including a 2025 study on low-molecular-weight heparin therapy in thrombophilia carriers, has reported similar directional findings, but the evidence base remains fragmented.

The study also carries implications for genetic screening in prenatal care. Factor V Leiden frequencies vary widely across populations, and prevalence data from countries including Nigeria, Pakistan, and Sudan, cited in the paper’s bibliography, show that the mutation is far from confined to European populations, where it was first described. Consanguinity, which the Egyptian team recorded as a baseline variable, can increase the likelihood of homozygosity for recessive variants and complicate genetic counseling. As genotyping becomes cheaper and more widespread, the question of who should be tested, and what a positive result should trigger clinically, grows more pressing. The authors’ own institution, a prenatal diagnosis and fetal medicine department, reflects the growing integration of molecular genetics into obstetric decision-making.

For now, the study offers a provocative and carefully bounded message: in this cohort of 200 women with heterozygous Factor V Leiden and prior adverse pregnancy outcomes, antenatal anticoagulation was associated with a nearly threefold increase in the likelihood of a normal pregnancy, driven largely by a reduction in small-for-gestational-age births. It is an association, not a prescription. But if larger randomized trials replicate the effect size reported here, one of the longest-running controversies in thrombosis and obstetrics could finally move toward a resolution, and a single-letter spelling change in a clotting gene might no longer cast such a long shadow over pregnancy.

Subject of Research: The effect of routine antenatal anticoagulation on pregnancy outcomes in women carrying the heterozygous Factor V Leiden mutation

Article Title: Association between routine anticoagulation and pregnancy outcomes in women with heterozygous Factor V Leiden genotype

Article References: M. Shaker, M., M. Elaraby, N., & A. shalabi, T. (2026). Association between routine anticoagulation and pregnancy outcomes in women with heterozygous Factor V Leiden genotype. Molecular Biology Reports, 53(1), Article 1599. https://doi.org/10.1007/s11033-026-12686-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12686-x

Keywords: Factor V Leiden, thrombophilia, anticoagulation, low-molecular-weight heparin, pregnancy outcomes, placental complications, small for gestational age, venous thromboembolism, genotyping, case-control study, obstetrics, recurrent pregnancy loss

The research, published in Molecular Biology Reports by Ivan Zivotic, Ivana Kolic, Mariana Seke, Milan Stefanovic, Ljiljana Stojkovic, Aleksandra Stankovic, Maja Zivkovic and colleagues, set out to systematically evaluate whether slow, intermediate and fast ramp rates produce measurable shifts in cycle threshold values, the Ct values that serve as the primary readout of qPCR experiments. The team used a commercial TaqMan SNP genotyping assay alongside two well-characterized housekeeping genes, GAPDH and PPIA, providing both a genotyping application and a gene expression application within the same experimental framework. Eleven heterozygous DNA samples and three RNA samples were analyzed, with each ramp rate condition tested across two independent runs to distinguish genuine systematic effects from ordinary run-to-run noise.

The technical logic behind the question is straightforward. During each PCR cycle, DNA strands must separate at high temperature, primers and probes must bind at lower temperatures, and the polymerase must extend the new strand. If the instrument transitions too quickly between these temperature plateaus, reagents may not fully equilibrate, annealing may be incomplete, and enzyme activity may be briefly suboptimal. Conversely, slower ramps extend the total run time, which is a practical concern for high-throughput laboratories and for point-of-care settings where speed is critical. Earlier work has shown that ramp rate can matter in specific contexts. Studies of rapid microfluidic thermocyclers and ultrafast PCR platforms have demonstrated that carefully engineered fast cycling can work, but also that faster quantitative protocols may lose sensitivity or show increased variability under some conditions.

The clinical stakes of this question are not trivial. Research on tuberculosis diagnostics, for example, has documented that widespread use of incorrect ramp rate settings can negatively impact the performance of commercial line-probe assays used to detect drug-resistant Mycobacterium tuberculosis, leading to calls for better thermocycler configuration in diagnostic laboratories. Those findings created a plausible expectation that ramp rate could similarly distort Ct values in qPCR, potentially affecting quantification of viral loads, expression of disease-related genes, and genotyping calls across countless laboratories. The Serbian team’s results, however, point in a different direction for standard probe-based qPCR chemistry.

Across both the genotyping assay and the gene expression assays targeting GAPDH and PPIA, the researchers observed no consistent effect of ramp rate on Ct values. When they compared slow, intermediate and fast ramp settings within individual runs, they did identify isolated statistically significant or borderline significant differences, including for the FAM-labeled probe used in the genotyping assay and for both housekeeping gene expression measurements. Yet these differences failed a crucial test of reliability: they were not reproduced consistently across independent runs or across pairwise comparisons between ramp rate conditions. In other words, a difference that appeared in one run might vanish in the next, a pattern more consistent with ordinary experimental variability than with a genuine systematic influence of heating speed.

The authors conclude that the observed effects appeared to be assay- and run-dependent rather than attributable to a consistent influence of ramp rate itself. This distinction carries real methodological weight. Ct values are inherently sensitive to many sources of noise, including pipetting variation, reagent preparation, optical fluctuations, sample quality and the stochastic behavior of amplification at low template concentrations. When a sporadic difference between two ramp rate conditions falls within the range of ordinary run-to-run variation, attributing it to the ramp rate would be a statistical overreach. By requiring reproduction across runs before claiming an effect, the study models the kind of cautious interpretation that the updated MIQE 2.0 guidelines encourage for quantitative PCR reporting more broadly.

The findings align with a body of work suggesting that modern qPCR chemistry is more forgiving of thermal cycling parameters than early protocols assumed. Probe-based detection chemistries such as TaqMan rely on the 5′ nuclease activity of the polymerase releasing a fluorescent reporter, and the accumulation of fluorescence over cycles integrates the kinetics of many individual extension events. Small perturbations in the seconds spent transitioning between temperatures may be buffered by the exponential nature of amplification, where each cycle’s yield feeds into the next. Nearest-neighbor thermodynamic analyses of nucleic acid hybridization also indicate that primer and probe binding equilibria are governed primarily by sequence and temperature rather than by the speed at which those temperatures are reached, provided the hold times at each step are adequate.

Nevertheless, the researchers are careful to frame their work as exploratory rather than definitive. The sample size was modest, with eleven heterozygous DNA samples and three RNA samples, and the assay panel was limited to a single commercial SNP genotyping assay and two housekeeping genes. The authors explicitly note that larger studies involving more assays and samples are needed to determine whether PCR ramp rate has a meaningful impact on qPCR performance and reproducibility under different experimental conditions. Different amplicon lengths, different polymerase formulations, different detection chemistries such as SYBR Green intercalating dyes, and different instrument architectures could all behave differently. Studies of amplicon length effects on real-time PCR results, for instance, show that the physical dimensions of the amplified product can influence outcomes, and it remains possible that longer amplicons interact with ramp rate in ways the short targets tested here do not.

For working laboratories, the practical message is one of measured reassurance rather than license for indiscriminate protocol changes. The results suggest that laboratories running standard probe-based qPCR assays need not worry excessively about modest differences in ramp rate settings between instruments, provided that validation is performed on the actual platform in use. This matters for multi-site studies, for laboratories that must transfer validated assays between different thermal cycler models, and for clinical settings where instrument availability varies. At the same time, the tuberculosis diagnostic literature demonstrates that some assays are genuinely sensitive to thermal cycling parameters, so blanket assumptions in either direction would be unwise. The sensible approach, consistent with the study’s conclusions, is empirical verification: run the assay under the intended conditions, confirm that Ct values and amplification efficiency remain within established acceptance criteria, and document the settings used.

The study also arrives at a moment when the qPCR field is actively revisiting its reporting standards. The MIQE 2.0 revision of the minimum information guidelines reflects growing recognition that technical parameters, instrument characteristics and data analysis choices all shape the reproducibility of quantitative PCR results. By systematically probing one such parameter and reporting both the significant and non-significant findings, the Belgrade team contributes to a more honest empirical picture of what actually drives Ct variability. Their work was supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia, and the underlying data are available within the paper and its supplementary materials. While the question of ramp rate effects is not fully closed, this exploratory study provides a useful data point: for the genotyping and gene expression assays tested, the speed at which the thermal cycler moved between temperatures left the fundamental quantitative output of qPCR essentially unchanged, an encouraging result for anyone who has ever worried that a slightly slower machine might quietly be skewing their numbers.

Subject of Research: Effect of thermal cycler ramp rate on cycle threshold values in quantitative real-time PCR genotyping and gene expression assays

Article Title: Limited effect of PCR ramp rate on qPCR Ct values: an exploratory study

Article References: Zivotic, I., Kolic, I., Seke, M., Stefanovic, M., Stojkovic, L., Stankovic, A., & Zivkovic, M. (2026). Limited effect of PCR ramp rate on qPCR Ct values: an exploratory study. Molecular Biology Reports, 53(1), Article 1690. https://doi.org/10.1007/s11033-026-12881-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12881-w

Keywords: qPCR, ramp rate, Ct values, thermal cycler, TaqMan assay, GAPDH, PPIA, genotyping, gene expression, amplification efficiency, MIQE guidelines, reproducibility

The type 1 diabetes genetic risk score, or T1D-GRS, is a tool that has already proven its worth in diabetes prediction and classification. It aggregates information from ten single nucleotide polymorphisms, or SNPs—individual positions in the genome where the DNA letter varies between people and where certain variants shift the probability of developing the autoimmune form of diabetes. Because the score draws on genetic variants that remain stable throughout life, it can help distinguish type 1 from type 2 diabetes in young adults and identify individuals at elevated risk long before symptoms appear. Crucially, the T1D-GRS and islet autoantibodies, the immune markers that signal the body’s attack on insulin-producing cells, act as independent predictors of diabetes, which makes pairing them particularly powerful for screening and diagnostic purposes.

The obstacle has always been practical rather than scientific. To calculate the score, laboratories traditionally need genomic DNA extracted from white blood cells, which involves purification, quantification and storage steps that add expense at every turn, before a single genotyping reaction has even been set up. The Exeter team reasoned that this entire pipeline might be unnecessary. Serum, the very material already used for islet autoantibody assays, contains extracellular DNA released from cells that burst during the clotting process. If that DNA were sufficient for genotyping, the same tube of blood could serve both the antibody test and the genetic score, eliminating the need for a separate DNA extraction altogether.

There was a catch, however, and it lay in the biochemistry of clotting. The extracellular DNA in serum comes from leukocytes that rupture as the blood clots, so the amount of genomic DNA available depends on how long the sample is allowed to clot before being spun down in a centrifuge. Many standard serum processing protocols specify clotting times of less than thirty minutes, a window that previous work suggested may be inadequate for releasing enough genomic DNA into the fluid. The researchers therefore designed their study to answer two linked questions: whether a direct-from-serum genotyping method could calculate the ten-SNP T1D-GRS accurately, and how strongly the answer depended on clotting time.

The technical setup was deliberately conventional, which is part of the method’s appeal. The team used TaqMan SNP genotyping assays, a widely adopted fluorescence-based qPCR chemistry, together with TaqPath ProAmp Master Mix, in tiny five-microliter reactions containing just one microliter of either purified DNA or raw serum. Plates, prepared on a Biomek i7 Automated Workstation and run for fifty cycles on a QuantStudio 12K Flex Real-Time PCR System, included positive and no-template controls, and genotypes were called automatically using commercial software. In other words, nothing exotic was required—only standard reagents, standard instruments and a single microliter of serum per SNP.

Accuracy came first. In a cohort of 116 matched serum and whole-blood-derived DNA samples sent to the Exeter Genomics Laboratory from across the UK and Ireland, all with clotting times exceeding 24 hours, both biospecimens achieved call rates above 95 percent across all ten SNPs on the first pass, with no repeated reactions. A complete T1D-GRS was obtained from 84.5 percent of serum samples compared with 96.6 percent of purified DNA samples, a statistically significant difference, but among the 94 samples where both approaches yielded a complete score, the results agreed perfectly—100 percent concordance. In a subset of 32 samples with sequencing data available, the serum-derived scores were again fully concordant, confirming that the shortcut does not come at the cost of correctness.

The clotting-time experiment revealed where the method’s limits lie. The team analyzed 122 serum samples with recorded clotting times ranging from 12 to 475 minutes, running every sample in duplicate on separate qPCR runs to check reproducibility. Splitting the cohort at the thirty-minute mark produced a striking contrast. Samples clotted for thirty minutes or less achieved a genotyping success rate of just 68.8 percent, a replicate discordance rate of 28.8 percent, and yielded a complete ten-SNP score in only 7.4 percent of cases. Samples clotted for longer than thirty minutes, by comparison, reached a 97 percent genotyping success rate, only 2.2 percent replicate discordance, and complete scores in 77.8 percent of samples—a difference the authors report as highly significant. Performance in this longer-clotting group closely matched that of the samples clotted for more than 24 hours.

The explanation, the researchers argue, is straightforward: insufficient clotting time leaves too little extracellular DNA in the serum for reliable amplification. This aligns with earlier findings that PCR-based genotyping from samples containing very low DNA concentrations—below roughly 56 picograms—is unreliable. The practical message for laboratories hoping to combine genetic and biochemical testing is that serum should be allowed to clot for more than thirty minutes before processing, a duration that does not compromise autoantibody assays. Where additional tests sensitive to proteolysis, glycolysis or other degradation processes are needed, the authors suggest an intermediate clotting window of more than thirty minutes but under about three hours may offer the optimal balance between DNA release and analyte preservation.

The implications extend well beyond the immediate assay. A direct-from-serum approach could unlock cost-effective genotyping in the many large frozen serum biobanks around the world where no extracted DNA exists, allowing researchers to mine decades of stored samples for genetic risk information without retrieving new blood draws. Although the study tested only ten SNPs, the low input volume of one microliter per SNP suggests the same logic could scale to larger genotyping panels or alternative genotyping chemistries. For clinical laboratories that lack DNA-extraction capability, the proof-of-principle result points toward direct, automated assays that run antibody and genetic tests in parallel from a single serum sample. The work was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre, and the authors note existing research funding and licensing arrangements with Randox Laboratories to develop a T1D-GRS assay, underscoring the translational momentum behind the approach. If the method holds up in broader validation, the humble serum tube—already the workhorse of clinical chemistry—may become a one-stop source for both immune and genetic markers of diabetes risk.

Subject of Research: A direct-from-serum genotyping method for calculating a type 1 diabetes genetic risk score

Article Title: A direct-from-serum method for calculating a type 1 diabetes genetic risk score

Article References: Spurrier, B., Oram, R. A., Thomas, N. J., & Locke, J. M. (2026). A direct-from-serum method for calculating a type 1 diabetes genetic risk score. Journal of Translational Medicine, 24(1), Article 1148. https://doi.org/10.1186/s12967-026-08930-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08930-4

Keywords: type 1 diabetes, genetic risk score, serum, genotyping, TaqMan, qPCR, SNP, islet autoantibodies, DNA extraction, clotting time, biobanks, precision medicine

The study, published in BMC Genomics by Aitor Almanza of Navarrabiomed and colleagues, addresses a gap that has widened as genomic medicine has scaled up. Next-generation sequencing has transformed precision medicine, but the analytical workflows behind it have become increasingly complex, involving multiple extraction steps, library preparations, batching events and platform transfers. Each handoff is an opportunity for error. While the frequency of sample misidentification may be low, the researchers note that the potential negative outcomes are worrying, particularly in clinical contexts where a wrong sample match can influence diagnosis or treatment decisions. Existing SNP-based quality control solutions, they argue, tend to rely on non-coding genetic markers or require advanced technologies that many laboratories do not have, leaving a need for small, robust panels that are portable across technologies, compatible with diagnostic panels, applicable across diverse populations and straightforward to implement in a wet lab.

The core idea behind the new panel is elegantly simple. Every person carries millions of genetic variants, and the specific combination of variants at a carefully chosen set of positions acts like a molecular fingerprint that is essentially unique to an individual. If a laboratory genotypes those positions in a sample at the start of a workflow and again at the end, or compares a sequencing result against a reference profile collected earlier, any mismatch immediately flags a possible sample swap or contamination. The challenge lies in choosing which variants to include. The markers must be highly discriminant, meaning that the chance of two unrelated people sharing the same profile is vanishingly small. They must also be compatible across platforms, so that a profile generated on a sequencer can be compared with one generated on a qPCR machine, and they must work reliably in populations around the world rather than being calibrated to a single ancestry group.

To build the panel, the team applied a stringent filtering pipeline designed to identify highly discriminant, cross-platform compatible genetic markers supported by predesigned TaqMan assays. TaqMan assays are a widely used qPCR genotyping chemistry in which fluorescent probes report which allele is present at a specific position, making the technology a staple of clinical molecular laboratories. By restricting the candidate markers to SNPs that already have validated, commercially available TaqMan assays, the researchers ensured that any laboratory with standard qPCR infrastructure could adopt the barcode without developing new reagents from scratch. They also prioritized SNPs that are already present in clinical sequencing panels, a decision with important practical consequences: it means the barcode can often be read directly from data that clinical laboratories are already generating, without any additional sequencing effort.

Population applicability was a central design criterion. A barcode that discriminates well in European populations but poorly in East Asian or African populations would be of limited use in the diverse patient cohorts of modern medicine. The researchers therefore prioritized markers with broad applicability across world populations, drawing on allele frequency data to ensure that the panel retains its discriminatory power regardless of the ancestry of the person being tested. This focus distinguishes the panel from earlier identity-testing approaches that were often optimized for specific populations or that relied on markers whose behavior across ancestries was less well characterized. The result is a barcode intended to be genuinely portable, both technologically and demographically.

The validation of the panel drew on the NAGENDATA cohort, a collection of neuropathology samples from Navarra, Spain, gathered under informed consent for research use and approved by the Research Ethics Committee of Navarra. The team used whole-genome sequencing data from 150 samples in the cohort to establish reference profiles and then cross-validated the barcode with qPCR genotyping. The numbers reported are striking. The full 44-SNP panel demonstrates exceptional discriminatory power, with theoretical cumulative random match probabilities ranging from 2.43 times ten to the power of minus nineteen in European populations to 9.37 times ten to the power of minus eighteen in East Asian populations. In plain terms, the probability that two unrelated individuals share the same 44-SNP profile is so small, on the order of one in many quintillions, that a matching profile can be treated as conclusive evidence of identity for practical purposes.

Cross-platform performance is where the panel earns its clinical credentials. When the researchers compared profiles generated by next-generation sequencing with those generated by qPCR, they found 99 percent concordance between the two technologies. That level of agreement matters because the whole point of a portable barcode is that a profile generated in one laboratory, on one instrument, can be trusted when compared against a profile generated elsewhere, on a different instrument, perhaps years later. A barcode that produced different answers depending on the platform would generate false alarms and erode confidence. The high concordance indicates that the selected SNPs genotype cleanly and consistently across chemistries, a property that reflects careful marker selection as much as analytical rigor.

The panel did not merely perform well in theory; it caught real errors. Combined within-platform and cross-platform analyses successfully identified three cases of sample mislabelling in the NAGENDATA collection. Those three detections, in a cohort of 150 samples, illustrate the kind of silent failures that can lurk in even well-managed biobanks and sequencing facilities. Without an independent genetic check, such mislabelled samples would have propagated through downstream analyses, potentially associating genomic data with the wrong individual and contaminating scientific conclusions. In a clinical workflow, the same failure could have far more serious consequences. The demonstration that a compact barcode can surface these errors retroactively, using data already on hand, underscores the practical value of the approach.

The researchers describe the result as a robust, ready-to-deploy SNP barcode that bridges next-generation sequencing and wet-lab workflows, enabling retrospective sample authentication across sequencing platforms and qPCR systems. The retrospective dimension deserves emphasis. Because many clinical sequencing panels already include the barcode SNPs, laboratories can often authenticate historical samples by extracting the relevant positions from existing sequencing files and comparing them against qPCR profiles or against other sequencing data. This opens the door to auditing past datasets for sample integrity issues without re-extracting DNA or re-running expensive assays, a capability that could be valuable for quality assurance programs, biobank certification and the growing movement toward reproducibility in genomics.

The design choices also reflect the regulatory and economic realities of clinical genomics. Sample tracking and data integrity sit at the intersection of privacy frameworks such as the GDPR and HIPAA, and laboratories need solutions that protect patient identity while verifying it. A 44-SNP barcode is deliberately minimal: it contains far too little information to reconstruct a person’s appearance, health risks or ancestry in any meaningful detail, yet more than enough to distinguish one individual from another. Combined with cost-effective implementation on equipment that most molecular laboratories already own, the panel lowers the barrier to routine sample authentication. As sequencing becomes ever more embedded in research and clinical routine, tools like this barcode point toward a future where every genomic dataset carries an internal, verifiable proof of its own provenance, quietly guarding against the swapped tubes and mislabelled plates that no laboratory is immune to.

Subject of Research: A TaqMan-compatible 44-SNP panel for cross-platform genetic sample authentication and tracking

Article Title: A TaqMan-compatible 44-SNP barcode for robust sample tracking in research and clinical settings

Article References: Almanza, A., Solaesa, V. G., Alvira-Iraizoz, F., Talavera, M. L. M., De Blas Rioja, P., Sanz-Solas, A., de los Mozos Aliaga, I. R., & Sánchez, Á. A. (2026). A TaqMan-compatible 44-SNP barcode for robust sample tracking in research and clinical settings. BMC Genomics. https://doi.org/10.1186/s12864-026-13282-w

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13282-w

Keywords: sample tracking, SNP barcode, TaqMan, genomics, next-generation sequencing, qPCR, whole-genome sequencing, biobank, data integrity, precision medicine, sample mislabelling, genotyping

Single nucleotide polymorphisms, or SNPs, are the workhorses of modern plant genetics. These single-letter variations in the DNA sequence are scattered throughout the genome, and by tracking which variants an individual carries, scientists can map genes responsible for traits, measure genetic diversity, and select the best breeding lines with unprecedented precision. For polyploid species like sheepgrass, however, building a reliable SNP panel is far harder than in diploids. Each SNP exists in up to four copies, and markers from the two subgenomes can be easily confused, producing noisy data that undermines downstream analyses. The new panel, developed by Lei Tian, Shuyi Hu, Xiaoyun Han, Chuifan Kong, and colleagues under the leadership of corresponding authors Gongshe Liu and Shuangyan Chen, was specifically designed to overcome these challenges.

The foundation of the panel was whole-genome resequencing of 100 diverse sheepgrass accessions, a strategy that allowed the researchers to survey variation across the entire genome before selecting the most informative markers. From this rich dataset, they applied rigorous filtering criteria to identify 51,696 high-quality SNPs suitable for targeted enrichment genotyping. The selection process prioritized markers with even distribution across all chromosomes, ensuring that no genomic region was left in the dark. Functional annotation of the chosen SNPs revealed that 64.3 percent sit within genic regions—the parts of the genome that contain or are close to genes—while 35.7 percent fall in intergenic regions. This balance is a significant strength, because markers inside or near genes are more likely to be linked to the variants that actually influence agronomic traits.

Density varied across the genome in ways that reflect the panel’s design and the underlying biology of the species. SNP density ranged from 3.94 SNPs per megabase on chromosome 3Ns to 8.92 SNPs per megabase on chromosome 2Xm, spanning both of the ancestral subgenomes that make up the allotetraploid complement. The nomenclature itself tells a story of sheepgrass’s evolutionary origins: the Ns and Xm designations refer to the two distinct progenitor genomes that hybridized to form modern Leymus species. By capturing markers across both subgenomes, the panel gives researchers the resolution needed to disentangle the genetic architecture of traits in a species where homologous chromosomes from different ancestors can masquerade as one another in sequencing data.

Technical performance is where the panel truly proves its worth. In validation experiments, the platform achieved genotype concordance above 98 percent, meaning that repeated genotyping of the same samples produces nearly identical results—a critical requirement for any tool intended for large-scale breeding programs. Call rates and coverage rates both exceeded 98 percent, indicating that the targeted enrichment chemistry reliably captures the intended loci across hundreds of samples in a single experiment. Perhaps most remarkably, the panel also showed strong transferability to other Leymus species, extending its usefulness beyond sheepgrass itself and opening the door to comparative genomics across the genus, which includes several other important forage and rangeland grasses.

To demonstrate the panel’s power in practice, the team genotyped 648 sheepgrass samples drawn from natural populations, hybrids, and cultivated varieties. The resulting data revealed clear genetic differentiation among these groups, painting a detailed picture of how wild and domesticated sheepgrass relate to one another. Notably, the analysis detected gene flow between wild and cultivated groups in breeding varieties, a finding with direct implications for breeders who want to preserve the adaptive diversity of wild populations while incorporating desirable traits into improved cultivars. Population structure analyses of this kind are essential for conservation planning as well, since they help identify which populations harbor unique genetic variation that may be crucial for adapting the species to future climates.

The panel’s most striking demonstration came in the form of a genome-wide association study, or GWAS, conducted on 276 accessions for five agronomic traits of central importance to forage breeding. GWAS works by scanning the genome for SNPs whose variants correlate systematically with differences in a measurable trait, exploiting the fact that markers near a causal gene tend to be inherited together with it. Using a mixed linear model framework that accounts for population structure and relatedness—both of which are substantial in a species spanning wild steppes and improved cultivars—the researchers identified significant loci associated with total number of spikes, grain weight per spike, and germination rate. These traits directly govern seed yield and establishment success, two of the biggest bottlenecks in sheepgrass cultivation and restoration.

Behind the statistical associations lie candidate genes with plausible biological roles. Among the genes pinpointed near significant loci were XIAO, a probable inactive leucine-rich repeat receptor kinase; KCS17, a member of the 3-ketoacyl-CoA synthase family involved in cuticle and wax biosynthesis; and ACO1, an aminocyclopropane-1-carboxylate oxidase that participates in ethylene biosynthesis. Each of these gene families has well-documented connections to plant development and stress responses, making them credible targets for follow-up functional studies. Receptor kinases like XIAO are known to regulate developmental signaling, while ethylene-related genes such as ACO1 influence seed germination and dormancy—precisely the trait for which the association was detected. The identification of these candidates illustrates how a well-designed SNP panel can compress the journey from field measurement to gene-level hypothesis into a single, cost-effective experiment.

Why does this matter beyond the laboratory? Sheepgrass dominates the typical steppe of Inner Mongolia and neighboring regions, where it provides critical forage for grazing animals and stabilizes soils against degradation. Overgrazing, land conversion, and climate change have placed enormous pressure on these grasslands, and restoration efforts depend on a reliable supply of improved seed with high germination rates and strong establishment. Traditional breeding in sheepgrass has been slow, hampered by the species’ perennial life cycle, outcrossing nature, and polyploid genetics. A 50 K SNP panel changes the calculus entirely: breeders can now apply marker-assisted selection to track favorable alleles for yield and vigor, use genomic selection to predict the performance of seedlings before they ever reach the field, and monitor genetic diversity within breeding programs to avoid the erosion of adaptive variation.

The cost-effectiveness of targeted enrichment genotyping is a further advantage. Whole-genome resequencing of every individual in a breeding program remains prohibitively expensive for most forage crops, which typically attract far less research investment than staple cereals. A fixed SNP panel strikes a middle path, delivering high-density genotyping at a fraction of the cost while producing data that are directly comparable across experiments, laboratories, and years. This standardization is what transforms a research tool into an infrastructure asset—one that can support everything from seed certification and variety protection to long-term monitoring of how steppe populations respond to environmental change. For a species that has waited decades for genomic resources to catch up with its ecological importance, the arrival of a robust, reproducible, and transferable 50 K SNP panel marks a genuine turning point, one that could accelerate the breeding of better sheepgrass cultivars just as the world’s grasslands need them most.

Subject of Research: Development of a 50 K SNP target-enrichment genotyping panel for the allotetraploid forage grass Leymus chinensis

Article Title: A 50 K SNP target‑enrichment panel for allotetraploid Leymus chinensis: empowering genomics and breeding in a complex forage grass

Article References: Tian, L., Hu, S., Han, X., Kong, C., Cheng, L., Qi, D., Liu, G., & Chen, S. (2026). A 50 K SNP target‑enrichment panel for allotetraploid Leymus chinensis: empowering genomics and breeding in a complex forage grass. BMC Plant Biology. https://doi.org/10.1186/s12870-026-10065-z

Image Credits: AI Generated

DOI: 10.1186/s12870-026-10065-z

Keywords: Leymus chinensis, SNP panel, allotetraploid, genotyping, GWAS, molecular breeding, forage grass, polyploidy, genetic diversity, population structure, candidate genes, Eurasian steppe

Single nucleotide polymorphisms, or SNPs, are the workhorses of contemporary genomics. These single-letter variations scattered across the genome allow scientists to fingerprint individuals, reconstruct family trees, trace population ancestry and, most importantly for breeders, predict which juvenile fish carry the genetic potential for fast growth, efficient feed conversion or disease resistance. High-density SNP arrays containing tens of thousands of markers deliver all of this information, but at a price per sample that becomes prohibitive when a breeding program needs to genotype thousands or tens of thousands of fish each generation. The cost barrier has been a major constraint on the large-scale application of genomic approaches in large yellow croaker, and the same problem afflicts many other aquaculture species where profit margins per animal are thin.

The new array was not built from scratch. The team started with NingXin-III, a previously established 55,000-marker array for the species, and systematically distilled it down to roughly 10,000 of the most informative SNPs. The selection strategy was deliberate rather than arbitrary: representative SNPs were chosen from haplotype blocks, the stretches of DNA that tend to be inherited together, so that each block would be covered by at least one marker capturing its variation. On top of that skeleton, the researchers supplemented the panel with SNPs at loci previously associated with economically important traits, ensuring the compact array retained predictive power where it counts most for selection decisions.

The technical performance of the trimmed panel proved remarkably strong. Across validation testing, the detection rate and genotype concordance, a measure of how faithfully the array calls each genetic variant compared with a reference standard, both exceeded 99 percent. The retained SNPs were also distributed evenly across all 24 chromosomes of the croaker genome, a critical property for any array intended to support genome-wide analyses, because clustering of markers on particular chromosomes would leave large genomic regions invisible to the platform. Even coverage means the 10 K panel can serve as a genuinely representative sample of the species’ genetic variation rather than a patchy snapshot.

Where the array truly earns its keep is in the suite of applied tests the researchers ran. In population genetic analyses, the panel effectively distinguished different croaker populations, a capability central to germplasm identification, the process of verifying that a batch of fry or broodstock genuinely belongs to the improved strain a hatchery claims it is. Machine learning classifiers built on the 10 K dataset, including logistic regression and random forest models evaluated with metrics such as the Matthews correlation coefficient and area under the receiver operating characteristic curve, achieved an accuracy exceeding 0.99 for germplasm identification, with results highly consistent with those obtained from the full 55 K array. In other words, cutting the marker count by more than 80 percent cost almost nothing in classification power.

Pedigree tracking delivered equally striking results. The array achieved 100 percent accuracy in parentage assignment, pedigree reconstruction and sex prediction. For breeding companies, parentage verification is not a luxury: without reliable family records, selective breeding programs cannot estimate heritabilities, control inbreeding or make accurate selection decisions, and mixed-up family assignments can quietly erode years of genetic gain. A cheap molecular pedigree check that works perfectly on every tested individual removes one of the most tedious and error-prone bookkeeping tasks in fish hatcheries, where thousands of families may be reared in shared tanks and physical tagging is impractical at scale.

Genomic selection, the most ambitious application, required an extra computational step. Because a 10 K panel samples only a fraction of the genome, the researchers used genotype imputation, statistical inference that fills in the untyped markers based on patterns of correlation with the typed ones, to reconstruct a denser dataset before running genomic prediction with the genomic best linear unbiased prediction (GBLUP) method. Imputation accuracy ranged from 0.817 to 0.964 depending on the scenario. After imputation, the 10 K panel retained genomic prediction performance close to that of the 55 K panel, although the authors are candid that the absolute predictive ability of both datasets was moderate, a reminder that prediction accuracy for complex traits such as body weight, feed conversion ratio and critical swimming speed depends on many factors beyond marker density, including reference population size and trait architecture.

One especially practical metric for breeders is how well a low-density array identifies the top performers in a population, since selection programs act on the best animals rather than on average prediction accuracy across the board. Here the imputed 10 K data held up well: among individuals ranked in the top 10 percent by genomic estimated breeding values (GEBV), the compact panel overlapped with the 55 K panel by 86.21 to 87.93 percent. That means a hatchery using the cheap array would catch the overwhelming majority of the same elite fish it would have flagged with the expensive one, at a fraction of the genotyping cost, making whole-population genomic selection economically viable for the first time in this species.

Beyond its immediate value for large yellow croaker, the study offers a template for other aquaculture breeding programs wrestling with the same cost calculus. The design logic, starting from a validated high-density array, pruning markers by haplotype block, enriching for trait-associated loci and validating across identification, parentage and prediction tasks, is directly transferable to other farmed fish, shrimp and shellfish. The authors position NingXin-IV as an efficient and cost-effective tool for germplasm evaluation, parentage verification, breeding strain management and large-scale genomic selection, and explicitly frame it as a useful reference for developing low-density platforms elsewhere in aquaculture. The research was supported by funding including the National Science Fund for Distinguished Young Scholars and the China Postdoctoral Science Foundation, with fish maintained at Ningde Fufa Fisheries Company Limited under institutional animal care protocols, fin clips collected after anesthesia with MS-222 and every sampled fish returned alive to its culture tank.

For an industry built on a fish that has been farmed in China for decades, the arrival of a sub-cent-per-marker genotyping platform may prove to be a quiet revolution. Cheaper genotyping means more animals screened per generation, faster genetic progress for traits farmers care about, and stronger protection of certified breeding lines against fraudulent substitution. It also means genomic tools long confined to well-funded laboratories can move into the routine operations of coastal hatcheries, where the daily decisions about which fish to keep as broodstock ultimately shape the future of the species. If the NingXin-IV experience is any guide, the future of aquaculture genetics may belong not to ever-larger arrays, but to smartly designed small ones that deliver nearly all the answers at a price the industry can actually pay.

Subject of Research: Development of a low-density 10 K liquid SNP array for genetic improvement and genomic selection in large yellow croaker

Article Title: Development and application of a low-density 10 K liquid SNP array for genetic improvement in large yellow croaker (Larimichthys crocea)

Article References: Li, Y., Wang, J., Zhao, J., Ke, Q., Jiang, P., Zeng, J., Weng, H., Pu, F., Zhou, T., Li, N., & Xu, P. (2026). Development and application of a low-density 10 K liquid SNP array for genetic improvement in large yellow croaker (Larimichthys crocea). BMC Genomics. https://doi.org/10.1186/s12864-026-13387-2

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13387-2

Keywords: large yellow croaker, SNP array, genomic selection, aquaculture, genotyping, Larimichthys crocea, parentage assignment, germplasm identification, genotype imputation, BMC Genomics, selective breeding, machine learning

The core problem COSIGT addresses is one of depth. Recent methods such as Locityper have already shown that pangenome references, which store many haplotypes as paths through a graph rather than a single consensus sequence, can dramatically improve targeted genotyping at difficult loci when read data are abundant. Locityper aligns reads to locus-specific haplotypes and selects the best-fitting diploid pair by optimizing alignment accuracy, insert-size concordance, and coverage balance. But that alignment-based likelihood machinery has an Achilles heel: as sequencing coverage falls, the signal-to-noise ratio degrades and genotyping accuracy drops with it. That matters enormously for population-scale studies and biobank cohorts sequenced at variable and often shallow depth, and it matters even more for ancient DNA, where postmortem degradation and microbial contamination routinely push effective coverage below 2X.

COSIGT takes a fundamentally different mathematical route. The pipeline first constructs a local variation graph for the target locus from haplotype-resolved assemblies, rather than querying an entire genome-wide pangenome. This locus-specific design allows parameter tuning, rapid incorporation of new assemblies, and faster genotyping. Reads pre-aligned to the region are extracted, supplemented with unmapped reads rescued by a k-mer filtering tool called kfilt, and then mapped to the local graph. From the graph nodes that reads traverse, the pipeline builds a coverage vector for the sample, in which each element reflects length-normalized, multi-mapping-aware coverage at a node. Every haplotype in the graph is likewise represented as a coverage vector of node traversal counts. COSIGT then enumerates all possible diploid haplotype pairs, sums their vectors to create synthetic genotype profiles, and computes the cosine similarity between each synthetic profile and the observed sample vector. The pair with the highest similarity wins.

The elegance of the approach lies in what cosine similarity measures. Because the metric captures the orientation of a vector rather than its magnitude, it is inherently invariant to overall sequencing depth. A sample sequenced at 1X coverage produces the same relative coverage profile shape as one sequenced at 30X, merely scaled down, and cosine similarity is blind to that scaling. Likelihood-based methods, by contrast, depend on absolute read counts and lose power as counts dwindle. In benchmarks across 326 challenging medically relevant genes and 265 structurally variable regions using short-read data from the 1000 Genomes Project, with pangenome graphs built from assemblies of the Human Pangenome Reference Consortium and the Human Genome Structural Variation Consortium, both COSIGT and Locityper performed well at 5X and 30X coverage, with more than 93 percent high-quality calls. Locityper retained an edge at 30X, reaching 98.2 percent versus 93.9 percent for COSIGT at the medically relevant genes.

At low coverage, the picture reversed dramatically. At 1X, COSIGT delivered 93.4 percent of calls at mid-or-higher quality compared with 84.5 percent for Locityper, and at 2X the gap persisted at 95.8 percent versus 93.4 percent. The advantage became even starker on simulated ancient DNA. Across 48 medically relevant genes enriched for pharmacogenetic and immunogenetic content, including HLAs, CYPs, and mucins, COSIGT maintained roughly 94 percent mid-or-higher quality calls at 1X while Locityper fell to about 46 percent; at 2X the figures were roughly 95 percent versus 60 percent. COSIGT outperformed Locityper at all 48 genes and showed only marginal degradation relative to matched modern DNA at the same coverage. The simulations, generated with a purpose-built simulator called ancestralsim, incorporated realistic ancient DNA damage patterns, short fragment lengths, and contamination levels of 0 or 10 percent, making the result a demanding test.

Robustness to missing references was assessed through leave-all-out benchmarks, in which the true haplotypes of each sample were excluded from the pangenome graph. Even then, COSIGT remained near-optimal, achieving at least 87 percent of the best possible quality at most loci, with 87.6 percent of medically relevant genes and 90.8 percent of structural variant regions falling in the top quintile of achievable quality. An ancestry-mismatched test, in which Peruvian and Colombian samples were genotyped against a graph containing no admixed American assemblies, yielded 87.2 percent high-quality calls at the medically relevant genes, suggesting the method degrades gracefully when the reference panel does not perfectly match the population under study.

The team also demonstrated the tool at genuine population scale. Applying COSIGT to 1,085 whole-genome samples from the Italian Moli-sani cohort, sequenced at roughly 20X coverage, the researchers performed HLA typing across seven classical HLA genes and achieved a mean haplotype-level accuracy of 89.5 percent against types imputed with HLA*IMP:02 from microarray data, comparable to the 90.8 percent achieved by the dedicated HLA genotyping tool T1K. More broadly, the authors report having applied COSIGT to more than 6,000 modern and ancient human genomes, demonstrating population-scalable analysis of complex repeats and multi-copy genes. The pipeline is implemented in Snakemake with containerized deployment, parallelizes across regions and samples, and its per-sample genotyping steps are computationally light, with a median runtime of about 0.02 minutes and median memory use of 52 megabytes for the core genotyping step.

The authors are candid about limitations. Genotyping accuracy ultimately depends on the quality and completeness of the input pangenome: haplotypes absent from the reference panel cannot be called exactly, and novel structural variants will be assigned to the most similar available haplotype. The leave-all-out benchmarks quantify how much accuracy survives this constraint, but they also make clear that expanding pangenome references remains essential. COSIGT currently requires pre-aligned BAM or CRAM files, creating a dependency on reference-based alignment, though future work aims to accept raw FASTQ input directly and to implement haplotype subsampling to keep the method scalable as pangenomes grow. The framework also currently supports diploid genotyping, although the underlying mathematics generalizes to arbitrary ploidy by enumerating k-tuples of haplotypes.

The implications reach well beyond a single software release. Pangenome references are expanding rapidly in size, quality, and taxonomic breadth, and as they do, the bottleneck shifts from reference completeness to scalable genotyping. By making complex-locus genotyping reliable at 1 to 2X coverage, COSIGT opens the door to systematically mining the vast archives of low-coverage sequencing data already sitting in biobanks and legacy datasets, and to bringing archaeological and ancient genomes into population-level biomedical analyses from which their shallow depth previously excluded them. Larger cohorts become affordable at reduced sequencing cost, samples of heterogeneous quality can be combined in a single analysis, and the allelic diversity captured in pangenome references becomes practically accessible across the full spectrum of sequencing depths. The pipeline is compatible with long-read input as well, which could extend its utility to low-coverage long-read datasets too sparse for assembly. For a field that has long treated structurally complex loci as terra incognita in shallow data, the message is that the map, and the compass to read it, may finally have arrived together.

Subject of Research: Pangenome graph-based genotyping of structurally complex genomic loci from low-coverage sequencing data

Article Title: COSIGT: population-scalable genotyping of complex loci from low-coverage sequencing data using pangenome graphs

Article References: Bolognini, D., Guarracino, A., Paleni, C., Dudley, T. S., Iacoviello, L., Raveane, A., Sudmant, P. H., Garrison, E., & Soranzo, N. (2026). COSIGT: population-scalable genotyping of complex loci from low-coverage sequencing data using pangenome graphs. Genome Biology, 27(1), Article 286. https://doi.org/10.1186/s13059-026-04242-4

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04242-4

Keywords: pangenome graphs, genotyping, low-coverage sequencing, ancient DNA, structural variation, copy-number variation, HLA typing, CYP2D6, cosine similarity, population genomics, Genome Biology, bioinformatics

Nanopore sequencing has transformed genomics by allowing DNA and RNA molecules to be read in their entirety, producing long reads that span entire transcripts and reveal complex splicing patterns that short-read technologies often miss. Oxford Nanopore platforms thread individual molecules through protein nanopores and infer their sequence from disruptions in an electrical current. This approach delivers reads that can stretch tens of thousands of bases, capturing full-length transcript isoforms and preserving modifications that are lost when RNA is fragmented and amplified. Yet the technology has long been hampered by a higher raw error rate compared with Illumina short-read sequencing, and this limitation has been particularly consequential for SNP calling, where a single misread base can be mistaken for a genuine variant.

Conventional approaches to correcting these errors typically rely on consensus building, aligning many reads to a reference genome and counting the frequency of each base at every position. Such methods work reasonably well for DNA sequencing at high coverage, but transcriptome data presents unique complications. Expression levels vary enormously across genes, meaning some transcripts are covered by thousands of reads while others yield only a handful. Low-coverage transcripts offer too few observations for statistical consensus methods to separate signal from noise, and highly expressed genes can harbor natural RNA editing events that complicate variant interpretation further. The result has been a landscape in which SNP detection from nanopore transcriptome data has demanded heavy computational filtering and often produced inconsistent results across tools and datasets.

NanoTS takes a fundamentally different approach by framing SNP calling as a pattern recognition problem that deep learning is exceptionally well suited to solve. Rather than relying solely on base-level alignments, the tool learns from the rich features embedded in nanopore signal data, the raw electrical current measurements that underlie every base call. Neural networks can detect subtle signatures that distinguish systematic sequencing errors, which tend to follow repeatable patterns tied to sequence context and pore dynamics, from genuine genetic variation, which manifests consistently across independent molecules. This capacity to model complex, high-dimensional relationships in the data allows NanoTS to make confident genotype calls even in regions where traditional statistical methods falter.

The implications of accurate SNP calling from direct RNA sequencing extend across a wide range of biological and biomedical applications. Variant detection at the transcript level reveals which alleles are actively expressed, a dimension invisible to DNA-based genotyping. Allele-specific expression, in which one copy of a gene is transcribed more abundantly than the other, plays a critical role in imprinted genes, autoimmune disease, cancer biology and X-chromosome inactivation. Researchers studying these phenomena have historically needed to combine DNA genotyping with RNA expression analysis from separate experiments, introducing uncertainty about whether observed expression patterns truly reflect the same cells and conditions. A tool that can call genotypes directly from transcriptome data collapses these two measurements into a single, internally consistent dataset.

The deep learning architecture at the heart of NanoTS represents part of a broader movement in genomics toward learned models that outperform hand-crafted algorithms. Basecalling, the process of converting raw nanopore current signals into nucleotide sequences, was revolutionized years ago by neural networks that replaced earlier hidden Markov model approaches, dramatically improving read accuracy. Variant calling is now following a similar trajectory. DeepVariant, developed by Google, demonstrated that convolutional neural networks could outperform classical statistical variant callers on Illumina data by treating genomic alignment piles as images. NanoTS extends this paradigm to the specific and demanding context of long-read transcriptome sequencing, where error profiles, coverage distributions and biological variation patterns differ substantially from genomic DNA sequencing.

Training such a model requires data of exceptional quality, since the network must learn to associate signal and alignment patterns with known ground-truth genotypes. The developers of NanoTS tackled this challenge by curating training examples in which true variants could be established with high confidence, allowing the network to internalize the distinctions between authentic polymorphism and sequencing artifact. Once trained, the model generalizes across genes, transcripts and coverage regimes, producing variant calls that remain reliable even for transcripts sequenced at low depth, a scenario that has historically been the Achilles heel of long-read transcriptome analysis.

The clinical dimension of this work is particularly compelling. Personalized medicine increasingly depends on knowing both which variants a patient carries and how those variants are expressed in relevant tissues. RNA sequencing of patient samples, whether from tumor biopsies or blood cells, is already routine in many clinical and research settings. If those same RNA reads can yield accurate genotype information without a parallel DNA sequencing run, the cost and complexity of comprehensive molecular profiling drops considerably. Cancer genomics stands to benefit substantially, as tumor transcripts carry both expressed mutations and the allele-specific expression patterns that reveal loss of heterozygosity and other genome alterations relevant to treatment decisions.

Beyond clinical applications, NanoTS opens doors for basic research into population genetics and evolutionary biology at the transcript level. Understanding how genetic variation shapes transcript diversity across individuals and species requires tools that can reliably measure both. Long-read transcriptome sequencing captures the full complexity of isoform expression, and with accurate SNP calling layered on top, researchers can begin to map how specific variants influence splicing, expression levels and transcript structure in ways that short-read studies have only approximated. The combination of full-length isoform resolution and direct genotype calling provides a uniquely integrated view of the relationship between genome and transcriptome.

The publication of NanoTS in Nature Methods underscores the growing recognition that computational innovation is as essential to unlocking the potential of new sequencing technologies as the hardware itself. As nanopore sequencing continues its rapid improvements in accuracy and throughput, tools like NanoTS ensure that the analytical pipeline keeps pace, converting noisy raw signals into biologically meaningful and clinically actionable insights. For laboratories worldwide working with direct RNA sequencing, the arrival of a robust deep learning solution for SNP calling marks a significant step toward making long-read transcriptomics a complete, standalone platform for both discovery and diagnosis.

Subject of Research: A deep learning tool for accurate SNP calling and genotype detection in nanopore long-read transcriptome sequencing data.

Article Title: NanoTS: a deep learning tool for accurate SNP calling in nanopore long-read transcriptome data

Article References: Liu, Z., Wang, F., Wang, R., Wu, D. W., DeBruyne, N., Keith, K., McCormick, E. M., Park, J. J.-H., Sullenberger, M. T., Edmondson, A. C., Falk, M. J., Lin, L., & Xing, Y. (2026). NanoTS: a deep learning tool for accurate SNP calling in nanopore long-read transcriptome data. Nature Methods, 23(10), 1968-1972. https://doi.org/10.1038/s41592-026-03225-4

Image Credits: AI Generated

DOI: 10.1038/s41592-026-03225-4

Keywords: NanoTS, deep learning, SNP calling, nanopore sequencing, long-read transcriptomics, genotyping, direct RNA sequencing, variant detection, neural networks, Nature Methods, allele-specific expression, computational genomics